Programma

Het programma van het Nationale Longkankersymposium is op dit moment nog niet beschikbaar. Zodra het gereed is, wordt het hier gepubliceerd.

Print programma
Vrijdag 15 januari

Session 4 || Sushil Badrising & Sjaak Burgers/Frank Borm

Coffee break

Tijd: 10:45 - 11:28

Antibody Drug Conjugates

Tijd: 15:55 - 16:20
Dr. Jordi Remon, Longarts, Gustave Roussy

KRAS mutated NSCLC

Tijd: 15:30 - 15:55
Prof. dr. Alessandra Curioni, Director and Chair, University and Hospital Fribourg

How to navigate through the first line treatment options of EGFRm positive NSCLC

Tijd: 14:40 - 15:05

Multiple new drugs have been introduced in the recent years for EGFR mutation positive NSCLC, both in first as well as later lines. Choosing the first line regimen has consequences for later line options. In this presentation we will discuss how to navigate through the field of these innovations.

Joop de Langen, Longarts, NKI-AVL

A multidisciplinary approach to stem cell therapy for airway fistulas

Tijd: 14:15 - 14:40
Hans Kemming, longarts, UMC Utrecht

Lung Cancer from an evolutionary perspective: therapeutic consequences. TRACERx study

Tijd: 13:45 - 14:15
Ariana Huebner, University College London

Vera Bonta Award 2026

Tijd: 13:30 - 13:43

Screening without losing; use of risk models in Lung Cancer Screening

Tijd: 11:55 - 12:20
Prof. Oluf Dimitri Røe, Norwegian University of Science and Technology

Are biomarkers a useful tool for early detection of lung cancer?

Tijd: 11:30 - 11:55
Dr. Luis Seijo, Clínica Universidad De Navarra

Optimizing radiotherapy in combination treatment for SCLC

Tijd: 10:20 - 10:45

Klik hier voor een samenvatting

Bjørn Henning Grønberg, Norwegian University Of Science And Technology

New drugs, new side effects: Cytokine Release Syndrome and other toxicities

Tijd: 09:55 - 10:20
Prof. dr. Anne-Marie Dingemans, Longarts, Erasmus MC

Finally: New treatment options for small cell lung cancer patients

Tijd: 09:30 - 09:55
Prof. dr. Martin Schuler, University Hospital Essen

Session 3 || Moderators: Joop de Langen & Frank Borm

Session 2 || Moderators: Sjaak Burgers & Wieneke Buikhuisen

Session 1 || Moderators: Gerrina Ruiter & Jasper Smit

Welcome

Tijd: 09:25 - 09:26
Sjaak Burgers

Coffee served in the conference room

Drinks

Tijd: 16:20 - 17:00

Who can we spare immunotherapy? Biomarkers

Tijd: 16:00 - 16:05
Prof. dr. Alessandra Curioni, University Freiburg, Switzerland

Targeted treatment in early stage NSCLC

Tijd: 15:00 - 15:05
Dr. Suresh Ramalingan, Emory University, United States

First line options for EGFR+ NSCLC

Tijd: 14:30 - 14:35
Prof. dr. David Planchard, Thoracic oncologist, Gustave Roussy

Lunch

Tijd: 12:20 - 13:30

What to do with all these data?

Tijd: 10:50 - 10:55
Dr. J.A. de Langen

Immunotherapy and comorbidities, the side effect treatment beyond steroids

Tijd: 15:30 - 15:35
Prof. Jarushka Naidoo, Medical Oncologist, Beaumont Hospital And RCSI University

”Are you NUTs”? Diagnostical and molecular challenges in squamous cell lung cancer

Tijd: 12:10 - 12:15
Dr. Gerrina Ruiter, Longarts, AVL

Vaping: A lifeline for ‘chain smokers’ or a ‘Trojan horse’? And what is our responsibility?

Tijd: 14:00 - 14:05
Frank Borm, Longarts, LUMC

Coffee break

Tijd: 15:05 - 15:28

Surgery is key in the treatment of stage III NSCLC. 

Tijd: 10:25 - 10:26
Prof. Eric Lim, Brompton, London

Radiotherapy is key in the treatment of stage III NSCLC

Tijd: 10:00 - 10:05
Prof. Dr. Med. Matthias Guckenberger, University Hospital, Zurich

Neo-adjuvant therapy: lessons from other malignancies (than NSCLC)

Tijd: 11:40 - 11:45
Dr. Myrjam Chalabi, Internist-oncoloog, NKI-AVL

The Legend of the RECIST criteria: Will Artificial Intelligence Take Over Tumor Measurement?

Tijd: 09:30 - 09:35
Dr. Kevin Groot Lipman, NKI-AVL
Illaa Smesseim, longarts en arts-onderzoeker, NKI-AVL

Registration

Tijd: 09:00 - 09:27
Home › Programma
Website en marketing